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Virology, epidemiology, pathogenesis, and control of 
enterovirus 71
Tom Solomon, Penny Lewthwaite, David Perera, Mary Jane Cardosa, Peter McMinn, Mong How Ooi 
First isolated in California, USA, in 1969, enterovirus 71 (EV71) is a major public health issue across the Asia-Pacifi c 
region and beyond. The virus, which is closely related to polioviruses, mostly aff ects children and causes hand, foot, 
and mouth disease with neurological and systemic complications. Specifi c receptors for this virus are found on white 
blood cells, cells in the respiratory and gastrointestinal tract, and dendritic cells. Being an RNA virus, EV71 lacks a 
proofreading mechanism and is evolving rapidly, with new outbreaks occurring across Asia in regular cycles, and 
virus gene subgroups seem to diff er in clinical epidemiological properties. The pathogenesis of the severe 
cardiopulmonary manifestations and the relative contributions of neurogenic pulmonary oedema, cardiac dysfunction, 
increased vascular permeability, and cytokine storm are controversial. Public health interventions to control outbreaks 
involve social distancing measures, but their eff ectiveness has not been fully assessed. Vaccines being developed 
include inactivated whole-virus, live attenuated, subviral particle, and DNA vaccines. 
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Enteroviruses are small, single-stranded, positive-sense 
RNA viruses from the enterovirus genus in the family 
Picornaviridae.1 They cause disorders with a wide range 
of clinical manifestations, including cutaneous, visceral, 
and neurological diseases. For many years polioviruses 
were the most important enteroviruses, since they led to 
large outbreaks of paralytic disease. A global campaign 
has, however, almost eradicated poliomyelitis from many 
regions worldwide. In its place, enterovirus 71 (EV71) 
causes major outbreaks of hand, foot, and mouth disease 
(HFMD), most frequently aff ecting children. This virus 
was fi rst described in 1969,2 although an analysis shows 
that EV71 was circulating in the Netherlands as early as 
1963.3 Although present in most countries, the largest 
outbreaks of disease have been seen in the Asia-Pacifi c 
region, for reasons that are incompletely understood.4–16 
The neurological manifestations range from aseptic 
meningitis to acute fl accid paralysis and 
brainstem encephalitis, which is associated with systemic 
features, such as severe pulmonary oedema and shock, 
in many cases.17,18 The clinical features, investigations, 
and management of severe EV71 disease are discussed 
in a companion article in The Lancet Neurology.19 In this 
Review we consider the virology, clinical and molecular 
epidemiology, pathogenesis, and prospects for control.
Virology
Classifi cation
As well as the enterovirus genus, the large Picornaviridae 
family includes Rhinovirus spp (eg, the common cold), 
Hepatovirus spp (eg, human hepatitis A virus), 
Parechovirus spp (eg, human parechovirus 1 and 2), and 
two important animal virus genera, Cardiovirus spp (eg, 
encephalomyocarditis virus) and Aphthovirus spp (foot 
and mouth disease virus).1 Human enteroviruses were 
traditionally separated into four classifi cations, according 
to their pathogenicity in human beings and experimental 
animals and their cytopathic eff ects in tissue culture; 
these subgroups were polioviruses (three serotypes), 
coxsackievirus A (23 serotypes), coxsackievirus B (six 
serotypes), and echoviruses (28 serotypes).1 However, 
because of the limitations of this system, serologically 
distinct human enteroviruses isolated since 1970 have 
been designated by serotype numbers, beginning with 
HEV68. The original classifi cation of human 
enteroviruses has been substituted by a taxonomic 
scheme based on molecular and biological properties of 
the viruses.20 This revised classifi cation recognises at 
least 90 subtypes and separates them into four species 
(table 1). Polioviruses have been designated as members 
of the human enterovirus C species because they are 
genetically closely related.21 
Physicochemical properties
The virus capsid comprises 60 identical subunits 
(protomers), each of which contains a copy of the four 
structural viral proteins (fi gure 1).22 The lack of a lipid 
envelope confers human enteroviruses stability in the 
host environment, including on exposure to human 
gastric acid, and they can survive at room temperature 
for several days. EV71 and other enteroviruses have also 
been detected in surface and ground water and in hot 
spas.23,24 Enteroviruses are resistant to organic solvents 
(eg, ether and chloroform), alcohol, and freezing, but 
can be inactivated by temperatures higher than 56°C, 
chlorination, formaldehyde, and ultraviolet irradiation. 
In one study EV71 was destroyed by virucidal 
disinfectants.25
Life cycle and replication
Human beings are the only known natural hosts of 
human enteroviruses. Like most other enteroviruses the 
replication cycle of EV71 is similar to that of polioviruses.26 
Viral entry into susceptible host cells is dependent on 
specifi c receptors. Seven receptors for diff erent 
enteroviruses have been identifi ed in human beings.20 
The specifi c receptors include the poliovirus receptor 
(CD155), three integrins (α2β1, αvβ3, and αvβ6), decay-
accelerating factor (CD55), the coxsackievirus-adenovirus 
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receptor, and intracellular adhesion molecule 1. Some 
enteroviruses use more than one receptor to infect a host 
cell. Several receptors for EV71 have been identifi ed, but 
a ubiquitously expressed cellular receptor, scavenger 
receptor B2, and a functional receptor, human P-selectin 
glycoprotein ligand-1, found on white blood cells, are 
specifi c for EV71.27,28 Sialic-acid-linked glycan, which is 
expressed in abundance in the respiratory and gastro-
intestinal tracts, and dendritic-cell-specifi c intercellular 
adhesion-molecule-3-grabbing non-integrin (CD209), 
which is found exclusively in dendritic cells in 
lymphoid tissues, have also been identifi ed.29–31 
After an enterovirus binds with a specifi c receptor on 
the cell surface, a series of structural changes occur in 
the virus capsid (yet to be defi ned in EV71) and pores are 
formed in the cell membrane through which the 
virion RNA is released into the host cell cytoplasm. 
Being positive-sensed, the parent virus RNA acts directly 
as a messenger RNA and is translated into a large 
polypeptide that is promptly cleaved by the viral 
proteases into 11 mature structural and non-structural 
proteins. The replication of the virus genome by the 
error-prone RNA-dependent RNA polymerase 3Dpol 
takes place in a vesicle membrane structure (viral 
replication complex). The polymerase is estimated to 
misincorporate one or two bases in every genome 
copying event, which explains why the virus mutates 
and evolves rapidly. Within the VP1 gene 4·2–4·6×10–3 
nucleotide substitutions occur per site per year, which is 
similar to the number in poliovirus and greater than 
that of infl uenza viruses.32–34 
While the machinery of the host cellular protein 
synthesis is shut down by viral protease 2A, viral protein 
synthesis remains unaff ected. An infectious virus particle 
is formed after the packaging of a progeny viral RNA into 
a virus capsid in the cytoplasm of the infected cells. 
Mature infectious virus particles are released when an 
infected cell is lysed. 
Clinical epidemiology
Initial identifi cation
EV71 was isolated from the stool of a child aged 9 months 
with encephalitis, in California, USA, in 1969,2 although 
an earlier isolate has since been identifi ed.3 Within 
5 years small outbreaks of neurological infections, 
including encephalitis and aseptic meningitis, attributed 
to EV71 were reported in Australia, Japan, Sweden, and 
the USA.35–39 
The dermotrophic properties of EV71 were fi rst 
recognised when the virus caused epidemics of HFMD 
in Japan in 1973.38,39 In the 1970s, two large EV71 epidemics 
occurred in Europe. The fi rst, in Bulgaria, was initially 
attributed to polioviruses because of the epidemiological, 
clinical, and pathological characteristics.40,41 EV71, 
confi rmed by virus isolation or neutralisation test, was 
later identifi ed as the causative agent in 347 (77%) of 
451 children who presented with non-specifi c febrile 
illness or neurological disease; 44 children died. The 
second major epidemic was 3 years later in Hungary, 
with 1550 cases (826 aseptic meningitis, 724 encephalitis) 
and 47 deaths reported; unlike the Bulgarian epidemic, 
few patients had HFMD.42 
Figure 1: Enterovirus 71 structure and genome structure of the virion 
Human enteroviruses are small (circumference around 30 nm), non-enveloped, icosahedral particles that contain 
a single-stranded, positive-sense, polyadenylated virus RNA of approximately 7·4 kb. Each protomer in the virus 
capsid contains a copy of the four structural viral proteins (VP1–VP4), of which VP1, VP2, and VP3 are external, 
whereas VP4 is completely internalised and is not, therefore, exposed to the host antibody response. All the 
structural proteins are encoded by the P1 region of the genome. The P2 and P3 regions encode seven non-structural 
proteins—2A–2C and 3A–3D. Reproduced from ViralZone, with permission of Swiss Institute of Bioinformatics, and 









VP4 VP2 VP3 VP1 2A 2B 3B 3C 3D AAA2C 3A
P1 P2 P3 3‘ UTR5‘ UTR
2000 3000 4000
Genome length in nucleotides
5000 6000 7000
Serotype
A CV-A2–8, CV-A10, CV-A12, CV-A14, CV-A16, EV71, EV76, EV89–92
B CV-A9, CV-B1–6, E1–7, E9, E11–21, E24–27, E29–33, EV69, EV73, EV74–75, EV77–88, EV93, EV97, EV98, EV100, EV101, EV106, EV107
C CV-A1, CV-A11, CV-A13, CV-A17, CV-A19–A22, CV-A24, EV95, EV96, EV99, EV102, EV104, EV105, EV109, PV1–3 
D EV68, EV70, EV94
The Picornaviridae Study Group and the International Committee on Taxonomy of Viruses classifi ed the Enterovirus genus into ten species, which include four human 
enterovirus species (A–D), three human rhinovirus species (A–C), bovine enterovirus, simian enterovirus A, and porcine enteroviruses (http://www.ncbi.nlm.nih.gov/ICTVdb/
ICTVdB/). CV-A=coxsackievirus A. CV-B=coxsackievirus B. EV=enterovirus. E=echovirus. PV=poliovirus.
Table 1: Human enterovirus serotypes, by species 
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Asia-Pacifi c region
After the Australian and Japanese EV71 epidemics of the 
1970s, further small epidemics and sporadic clusters 
occurred in Hong Kong in 1985,43 and in Australia in 1986.44 
In 1997, a large outbreak of EV71 in Sarawak, Malaysia, 
heralded the start of a new series of outbreaks across the 
Asia-Pacifi c region (table 2).9–14,45–53
In Sarawak, 2618 HFMD cases and 34 deaths were 
recorded between May and July, 1997; around the same 
time EV71 caused four deaths in peninsular Malaysia 
and several cases of severe neurological disease in 
Japan.4,11,54 In 1998, the largest EV71 epidemic so far 
occurred in Taiwan:7 an estimated 1·5 million people 
were infected and 405 children were admitted to 
hospital for serious neurological complications, of 
whom 78 died. The latest large Asian-Pacifi c epidemic 
was in China in 2008, when around 490 000 infections 
and 126 deaths in children were reported; at the 
epicentre in Anhui Province, more than 6000 HFMD 
cases and 22 deaths in children were reported.12 In 
addition to these very large outbreaks, many areas, 
including Japan, Sarawak, Singapore, Taiwan, and 
Vietnam, have experienced cyclical epidemics that occur 
every 2–3 years (fi gure 2).55–57
Brainstem encephalitis, especially aff ecting the 
medulla, associated with cardiopulmonary dysfunction 
has become a notable feature in EV71 epidemics in Asia, 
and is the primary cause of death.4,9,12,17,58 This presentation 
is in contrast to that in the 1980s, when aseptic meningitis 
was the most frequent neurological involvement.36,37 
Children typically present with a brief febrile illness and 
mild neurological signs, after which they develop signs 
of tachycardia, poor perfusion, and tachypnoea that 
rapidly develop into acute, intractable cardiac dysfunction 
and fulminant—in many cases fatal—pulmonary oedema 
or haemorrhage.19 Neurogenic pulmonary oedema is 
thought to be the main pathogenic process.17,18,54,59
Other regions
Outside the Asia-Pacifi c region, EV71 has continued to 
circulate at a low level in Africa, Europe, and the USA and 
causes sporadic cases or small outbreaks. During a 1-year 
prospective study in Canada in 1998, 20 children with EV71 
were admitted to a tertiary hospital, mostly in the summer 
or autumn months; half had aseptic meningitis, and a 
third had respiratory symptoms, but no symptoms were 
severe and all improved rapidly.60 Two small community 
out breaks of neurological EV71 disease, without HFMD, 
occurred in 2003 and 2005 in Denver, CO, USA, aff ecting 
16 children aged 4 weeks to 9 years; one child died.61 A 
retro spective analysis of stool samples collected from 
children admitted to hospital with aseptic meningitis in 
Austria between 2001 and 2004 showed that EV71 was 
detected in 16 (9%) of 181.62 A similar study identifi ed 
32 sporadic cases of EV71 infection in the UK between 
1998 and 2006, presenting primarily as neurological 
disease, HFMD, or both.63 In the Netherlands, 58 people 
were admitted to hospital with EV71-associated fever, 
gastrointestinal symptoms, and CNS infections in 2007, 
after 21 years of low endemicity.3 Widespread asymptomatic 
circulation of EV71 was also noted between October 2002 
and October 2003 in Norway, where the virus was isolated 
from 19 (17%) of 113 well children.64 EV71 was among a 
range of enteroviruses detected by the screening of blood 
donations in Scotland over 22 months; the detection rate 
for any enterovirus was one per 4000 donations,65 although 
the importance of this fi nding remains uncertain. In 
Nairobi, Kenya, two small institutional outbreaks of EV71 
infection were reported in an HIV orphanage in 
1999 and 2000.66
Molecular epidemiology
Gene groups, evolution, and geographical distribution
Phylogenetic analysis suggests that EV71 emerged from 
the coxsackievirus type A 16, as recently as 1940.32 The 
1973 1980 1986 1990 1993 1994 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Singapore .. .. .. .. .. .. B3, B4 B3, C1 B3 B4* B4 C1, B4 B4 - - B5 - B5
Peninsular 
Malaysia
.. .. .. .. .. .. B3*, B4*, 
C1†, C2†
C1 B4, C1 B4*, 
C1*
- - - - B5*, C1 - - -
Sarawak, 
Malaysia
.. .. .. .. .. .. B3* C1 None‡ B4*, 
C1
None‡ C1 B5, C1 None‡ B5 B5   
Perth, 
Australia
.. .. .. .. .. .. .. .. B3, C2 C1 None‡ None‡ - - - - - -
Japan B1 .. .. B2, C1 B2 C3 B3, B4, C2 C2 C2 B4 C2 B4, C2 C4, B5 C4 - C4 C4 -
Taiwan .. B1 B1 .. .. .. .. C2*, B4† B4 B4* B4 B4, C4† B4, B5† C4* C4*, C5† C5 C5, B5 B5*
Korea .. .. .. .. .. .. .. .. .. C3* None‡ None‡ C4 - - - - -
Brunei .. .. .. .. .. .. .. .. .. - - - - - - B5 - -
Vietnam .. .. .. .. .. .. .. .. .. - - - - - C1, C4, C5 - - -
Thailand .. .. .. .. .. .. .. .. .. - - C1 C1 C1 - B5, C1, 
C2, C4




China .. .. .. .. .. .. C3 C4 .. C4 C4 C4 C4 C4 - - C4 C4
*Genotypic subgroups caused large outbreaks. †Genotypic subgroup isolated in a small number of patients. ‡No enterovirus 71 detected, despite active surveillance. 
Table 2: Enterovirus 71 genotypic subgroups reported to be circulating in the Asia-Pacifi c region between 1973 and 2008, by year9–14,45–53
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fi rst complete phylogenetic analysis of EV71 based on 
the structural VP1 gene identifi ed three independent 
lineages of EV71, designated A, B, and C;53 each group 
has at least 15% divergence from the others. Group A 
consists of one member, the prototype BrCr strain, 
which was fi rst identifi ed in California, USA, in 1970, 
and was not reported outside the USA until 2008, when 
isolates were reported from fi ve of 22 children presenting 
with HFMD in Anhui province of central China.67 
Sequencing of the complete VP1 gene showed very little 
divergence between isolates. The virus might, therefore, 
have been circulating undetected in central China, with 
very little evolutionary change for 40 years, although the 
source of the virus templates that were sequenced could 
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have aff ected the results. Surveillance data from the 
same outbreak by the Chinese Center for Disease 
Control and Prevention do not seem to indicate any 
group A viruses.12 Good surveillance programmes are 
needed in many diff erent geographical regions to 
provide accurate and relevant information about EV71 
transmission and evolution, and to confi rm whether 
group A viruses have re-emerged.
The B group has been predominant in Malaysia and 
Singapore, whereas the C group has been so in east Asia, 
especially in mainland China and Vietnam (fi gure 3). 
Group B viruses, which were initially separated into 
subgroups, B1 and B2, owing to 12% divergence at the 
nucleotide level, were the predominant circulating strains 
in the 1970s and 1980s.53 Group C viruses, which were 
initially separated into the C1 and C2 subgroups, were 
identifi ed in the mid-1980s (fi gure 3). Several subgroups 
have been added to groups B and C in the past 12 years, 
according to fi ndings in the Asia-Pacifi c region (fi gure 3, 
table 2). Viruses in subgroups B3 and B4 are thought to 
have both circulated in the region since 1997.13,14,45 
Subgroup B5, was fi rst isolated in Japan and Sarawak 
in 2003, caused epidemics in Brunei, Sarawak, and Taiwan 
in 2006.46,55,56,68 Except for the major community outbreak 
in Sydney in 1986, subgroup C1 viruses have been isolated 
mainly from sporadic cases since the mid-1980s, 
which suggests low-level circulation worldwide.53,69 
Subgroup C2 viruses caused the outbreak in 1998, and an 
outbreak in Perth, Australia, in 1999.8,13,47,70 Subgroup C3 
was isolated in Japan in 1994, and in Korea in 2000.13,16,71 
Subgroup C4 has been the predominant circulating 
subtype in mainland China since 2000, and has been 
reported in Japan, Vietnam, and Taiwan.9,12,14,47 Subgroup C5 
has been reported in southern Vietnam and Taiwan.9,46 A 
genetically distinct EV71 strain (R13223, Genbank 
accession number AY179600 to AY179602), with no genetic 
relationship to other EV71 strains, was isolated in India 
in 2001 from one child with acute fl accid paralysis.72 
Transmission and epidemic potential
Surveillance systems for EV71 established in several 
countries in the Asia-Pacifi c region, mainly to monitor 
transmission and spread, have provided information on 
virus evolution during outbreaks. In Sarawak, viral 
activity has increased every 3 years since 1997. This 
pattern is closely associated with increases in community 
incidence of HFMD.55 Regular cyclical epidemics have 
also been seen in Fukushima Prefecture, Japan.57 Such 
cyclical activity is assumed to relate to the availability of 
new birth cohorts of children who have not been exposed 
to the virus.73,74 Prediction of the epidemic potential of 
particular genotypic subgroups has proved diffi  cult, 
although some diff erences in virulence, judged by size of 
associated epidemics, exist.
Shifts in subgroup dominance have been reported in 
Sarawak and Vietnam.9,13,55 In Japan and Taiwan subgroups 
of the B and C viruses have caused epidemics at diff erent 
times (table 2).46,47,75 By contrast, in the Netherlands group B 
viruses were predominant before 1986, but since 1987 
dominance has shifted to group C viruses; cross-
neutralisation among the group B but not group C viruses 
is a possible explanation, although experimental data seem 
not to support this theory.3,76–78 Older subgroups of EV71 
have been circulating and causing low levels of disease for 
many years, whereas some of those in newly described 
subgroups, such as B5, possess antigenicity distinct from 
other viruses and might, therefore, have the potential to 
Figure 3: Phylogenetic analysis of enterovirus 71 VP1 gene sequences 
A neighbour-joining tree constructed with the Kimura-2 parameter as a model for nucleotide substitution. The 
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cause very large outbreaks.48,76 Although outbreaks have so 
far been confi ned to the Asia-Pacifi c region, increasing 
rates of travel mean that every region could be at risk.
Recombination
Recombination events occur frequently within enterovirus 
species,79 and recombination between EV71 viruses, and 
occasionally between EV71 and other enteroviruses, such 
as coxsackievirus types A 16 and A 8, has also been 
reported.48,80 Since recombination most often involves 
non-structural gene regions or untranslated regions, the 
use of PCR that amplifi es the VP1 gene region is thought 
to be robust for diagnosis.
Pathogenesis
Viral determinants of virulence
The factors that determine whether EV71 infection will 
be asymptomatic or lead to HFMD or severe neurological 
disease are unknown. For polioviruses, the 5´untranslated 
region and VP1 genes contain virulence determinants.26 
Several studies have, therefore, examined the relevant 
nucleotide sequences or the whole genome to compare 
isolates from fatal and non-fatal cases, but most isolates 
have been identical or nearly identical.81,82 The frequency 
of CNS disease and other severe complications of EV71 
infection has varied between Asian outbreaks, which 
suggests diff erences in virulence of subtypes. However, 
comparisons of outbreak data have been hampered by 
diff erences in study designs and viral diagnostic 
capabilities. 
Perhaps the strongest data that determinants of strain 
virulence have key roles in the pathogenesis of severe 
neurological disease come from outbreaks in 
Perth, Australia, and Sarawak. In Perth, in 1999, 
subgroups B3 and C2 were both circulating.45,70 C2 viruses 
linked to the Taiwan epidemic of 1998 were almost 
exclusively isolated from children with severe neurological 
disease, and only one isolate came from a case of 
uncomplicated HFMD.45,70 By contrast, B3 viruses, which 
were similar to those from the Sarawak 1997 epidemic, 
were isolated mainly from children with uncomplicated 
HFMD, aseptic meningitis, or those with neurological 
complications, none of whom died.8 In two discrete 
epidemics in Sarawak in which either B4 or B5 viruses 
were predominant, a study of 277 children with EV71-
associated HFMD showed that B4 viruses were less likely 
than B5 viruses to cause CNS infection or be part of a 
family cluster.83 
Dual infection
During the 1997 EV71 B3 virus outbreak in Sarawak, an 
adenovirus type 21 was isolated in the patients who died 
and in some with acute fl accid paralysis.4,84 The virus was 
detected at autopsy in sterile sites, such as cerebrospinal 
fl uid and brain and heart tissue, in more patients than 
EV71. This fi nding led to the suggestion that death was 
related to dual infection,4 but subsequent detailed 
studies, including longitudinal studies from Sarawak, 
have found no evidence of adenovirus 21 infection in 
other HFMD or neurological cases. Dual infection with 
EV71 and other viruses, including dengue and 
Japanese encephalitis, has been reported.83 Furthermore, 
adenovirus 21 has not been isolated in Sarawak 
since 1997.
Host susceptibility
Various factors could aff ect pathogenesis, especially 
partial cross-protective immunity from previous 
outbreaks, which might partly explain why young age is 
a risk factor for severe disease.73,74,85 One genetic study in 
Taiwan reported that HLA-A33 is associated with 
increased susceptibility to EV71 infection, although the 
role of MHC remains unknown.86 The researchers 
noted that HLA-A33 is more frequent in Asian 
populations than in white populations, which might 
explain the high number of EV71 epidemics in Asia. 
They suggested also that HLA-A2, in a mechanism yet 
to be defi ned, could be linked to the risk of 
cardiopulmonary failure in patients with EV71.86 The 
CTLA4 gene is an important regulator of T-cell 
cytotoxicity, and it has a role in the regulation of an 
immune response. In a study of 78 children with 
EV71 infection in Taiwan, those with meningo-
encephalitis had a higher frequency of G/G genotype at 
position 49 of exon 1 in this gene, than those without 
meningoencephalitis and controls.87 However, a 
subsequent study found no such association.86 
Pathophysiology of severe disease
Virus entry and spread
EV71 is transmitted predominantly via the faeco-oral 
route, but can also spread through contact with virus-
contaminated oral secretions, vesicular fl uid, surfaces or 
fomites, and in respiratory droplets.1 As with other 
enteroviruses, initial viral replication is presumed to 
occur in the lymphoid tissues of the oropharyngeal cavity 
(tonsils) and small bowel (Peyer’s patches), with further 
multiplication in the regional lymph nodes (deep cervical 
and mesenteric nodes), giving rise to a mild viraemia. 
Most infections are controlled at this point and remain 
asymptomatic. Further dissemination of enteroviruses to 
the reticuloendothelial system (liver, spleen, bone marrow, 
and lymph nodes), heart, lung, pancreas, skin, mucous 
membranes, and CNS coincides with the onset of clinical 
features. For EV71, viral shedding from the throat can 
occur up to 2 weeks after an acute EV71 infection, and 
virus can be isolated from stool for up to 11 weeks.88 
Epidemiological and experimental studies suggest that 
polioviruses can invade the CNS system through a 
disrupted blood–brain barrier or retrograde axonal 
spread along cranial or peripheral nerves. For EV71, 
studies in mice and assessment of the distribution of 
virus and infl ammation in fatal human cases implicate 
the latter route.88–91 
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Pathological fi ndings
CNS infl ammation predominantly aff ects grey matter 
of the spinal cord and the whole medulla oblongata, 
including the dorsal nucleus of the vagus, 
tractus solitarius, the nucleus, and reticular formation. 
The hypothalamus and subthalamic and dentate nuclei, 
and to a lesser degree motor cortex of the cerebrum, are 
also involved (fi gure 4).17,54,90,92–94 Infl ammatory changes 
were absent in cerebellar cortex, thalamus, basal 
ganglia, peripheral nerve, and autonomic ganglia.
Histopathological changes, characterised by perivascular 
cuff s, variable oedema, neuronophagia, and microglia 
nodules, are similar to those in encephalitis caused by 
other viruses.95 However, virus inclusion has not been 
observed, and viral antigens and RNA can be seen in 
only a few neuronal processes and phagocytic cells.90
 Severe pulmonary oedema and heart failure
Although fulminant pulmonary oedema is preceded by 
and closely associated with CNS involvement, its cause 
is unclear, especially whether neurogenic pulmonary 
oedema, cardiac dysfunction, increased vascular 
permeability, and cytokine storm contribute (fi gure 5). 
Neurogenic pulmonary oedema classically follows head 
injury. In these cases, raised intracranial pressure is 
thought to be important, but the pathogenesis is not 
completely understood. Experimental studies suggest that 
the hypothalamus, vasomotor centres of the medulla, and 
nuclei in the cervical spinal cord are important; lesions to 
various nuclei in these regions can increase activity along 
the sympathetic trunk, resulting in severe systemic and 
pulmonary hypertension and pulmonary oedema.96 
Damage to brainstem nuclei in poliomyelitis is thought to 
lead to pulmonary oedema of neurogenic origin.97 Thus, 
when severe pulmonary oedema was fi rst seen in 
EV71 encephalitis along with brainstem infl ammatory 
changes, oedema was thought to be neurogenic. Post-
mortem examination and MRI studies of children with 
EV71 brainstem encephalitis showed extensive 
infl ammation of grey matter of the spinal cord and the 
whole medulla oblongata.17,54,90,93,94 The observations of 
hyperglycaemia and leucocytosis were also postulated to 
be due to increased sympathetic discharges.98
Severe systemic and pulmonary hypertension is 
not always seen in children with EV71-associated 
pulmonary oedema.99–101 This disparity might arise 
because the changes in vascular pressures in neurogenic 
pulmonary oedema are only transient.96 Some 
commentators have argued that cardiac dysfunction is a 
major contributor to the pulmonary oedema. Although 
no histological or virological evidence of viral myocarditis 
is seen in patients with EV71 infection, raised 
concentrations of cardiac-specifi c troponin I suggest a 
degree of cardiac damage.18,54,101,102 An echocardiographic 
study in 11 children with EV71 brainstem encephalitis 
showed that cardiac function was impaired, indicated by 
substantially lowered left-ventricular ejection fractions.101 
Two children whose cardiac output was supported with a 
left-ventricular assist device survived, whereas all the 
others died.103 In a separate report the same researchers 
described very high concentrations of norepinephrine 
Figure 4: Pathological fi ndings in enterovirus 71 encephalitis 
(A) Parenchymal infl ammation (arrow) and perivascular cuffi  ng in the the medulla. Severely infl amed areas show 
(B) oedema (asterisk) and (C) neuronophagia (arrows). (D) More-subtle infl ammation can be seen in the motor 
cortex, with mild perivascular cuffi  ng (arrow) and parenchymal infl ammatory cells (circle). (E) Numerous 
CD68-positive macrophages/microglia (arrows). (F) A CD8-positive lymphocyte adjacent to a neuron (arrow). 
(G) Viral RNA in the anterior horn cells of the spinal cord (arrows). (H) Viral antigens in the neuronal body and 
process in the hypothalamus. (I) Adjacent section of the same neuron that was positive for viral RNA, and (J) 
adjacent section that was positive for antigen. Stains: haematoxylin and eosin (A–D), immunohistochemistry/
peroxidase/DAB (E, F), and ISH/nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (G). Original 
magnifi cations: ×4 (A), ×10 (B and D), ×40 (C and F), and ×20 (G). Modifi ed from the Journal of Neuropathololgy and 
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and epinephrine in three of the 17 children with left-
ventricular dysfunction.101 
Although  patients with EV71 infection do not have 
myocardial infl ammation, histological examination of 
cardiac ventricular tissue biopsy samples from six fatal 
cases and one survivor revealed notable coagulative 
myocytolysis, myofi brillar degeneration, and cardio-
myocyte apoptosis, which are the characteristic features of 
catecholamine-associated cardiotoxic eff ects.101,104 Thus, 
high catecholamine concentrations caused by brainstem 
encephalitis are purported to have a direct eff ect on cardiac 
function, as well as to cause pulmonary oedema via raised 
pulmonary pressures.
The other potential contributor to pulmonary oedema, 
increased vascular permeability, might arise secondary to 
the systemic infl ammatory response. Several studies have 
examined cytokine and chemokine profi les in 
EV71 patients with brainstem encephalitis: concentrations 
of interleukins 1B, 6, 10, and 13, tumour necrosis factor α, 
and interferon γ are all signifi cantly higher in patients 
with EV71 with pulmonary oedema than in those without. 
Several of these cytokines are mediators of increased 
Figure 5: The postulated pathogenesis of enterovirus-71-associated acute pulmonary oedema 
EV71=enterovirus 71. CNS=central nervous system. SVR=systemic vascular resistance. SBP=systemic blood pressure. HR=heart rate. LV=left ventricular.
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vascular permeability.105–107 High concentrations of several 
chemokines in plasma, including 10 kDa-interferon-γ-
induced protein, monocyte chemoattractant protein, 
monokine induced by interferon γ, and interleukin 8, 
have been reported in children with brainstem encephalitis 
and pulmonary oedema.108 Children with oedema also 
had depleted lymphocyte populations, especially 
CD4, CD8, and natural killer cells.87,107 Thrombocytosis, 
neutrophilia, and hyperglycaemia are all thought to refl ect 
a systemic infl ammatory response.105,107 Cytokines in the 
cerebrospinal fl uid are less studied than those in blood, 
but in one study patients with encephalitis complicated 
by oedema had high concentrations of interleukin 1b, 
compared with those who had encephalitis alone.105
The development of pulmonary oedema in patients 
with EV71 encephalitis seems to be strongly associated 
with dysregulation of systemic and CNS infl ammatory 
responses. This relation has formed at least part of the 
basis for anti-infl ammatory therapy with intravenous 
immunoglobulin, and the approach does seem to be 
eff ective.83,99,109–111
The exact mechanism for pulmonary oedema in 
EV71 encephalitis is unclear. Neurogenic mechanisms 
secondary to brainstem infl ammation seem to be 
important, but pathologically similar changes are seen 
in other encephalitides, such as Japanese encephalitis, 
without pulmonary oedema being such a prominent 
feature. Cardiac dysfunction and the eff ects of the 
systemic infl ammatory response on the vascular 
endothelium may also make important contributions. 
In-vivo models, including those in mice and non-
human primates, have replicated some of the features 
of severe EV71 disease, such as neuroinvasion with 
infl ammatory changes, but none has yet been able to 
reproduce the severe systemic features, such as 
pulmonary oedema.89–91,112–114
Prospects for control
Surveillance and social distancing
The only measures available for disease control are public 
health approaches. Since early intervention can lessen the 
spread of the virus, many countries in the Asia-Pacifi c 
region, including Japan, Malaysia, Singapore, Taiwan, 
and Vietnam, have implemented heightened surveillance 
for EV71.15,55,56,115,116 HFMD has now become a notifi able 
disease in many countries in the region.116 However, since 
other enteroviruses, such as coxsackievirus types A 8, 
A 10, and A 16, can cause HFMD, concurrent virological 
surveillance is necessary. This approach can also provide 
invaluable molecular epidemiological data that might 
help to track the spread of the virus across the region. 
Outbreak control measures are primarily targeted at 
interrupting virus transmission person to person and 
through contact with contaminated surfaces, toys, or 
fomites. Health education, therefore, focuses on 
personal hygiene and good sanitation, including 
frequent hand washing, proper disposal of soiled 
nappies, and disinfection of soiled surfaces with 
chlorinated (bleach) disinfectants. 
The transmission of enteroviruses, including EV71, is 
most effi  cient in crowded settings and, therefore, most 
countries in the region, including Malaysia, Singapore, 
Taiwan, Hong Kong, and China, have adopted social 
distancing measures, such as closures of childcare 
facilities and schools, and cancellation of public functions 
involving children.115,116 Little systematic research has been 
done to assess the eff ectiveness of such measures, but one 
study from Singapore seemed to show some benefi t.115 
However, the optimum timing for implementation—as 
soon as an HFMD outbreak is reported or after it is 
confi rmed to be caused by EV71—is unclear. In addition, 
the eff ectiveness of distancing measures, which have 
substantial socioeconomic implications, is uncertain. If 
EV71 is like other directly transmissible viruses, such 
controls will decrease the peak incidence of disease, but 
the outbreak could be prolonged and, therefore, the overall 
number of cases might not be lowered (Cardosa MJ, 
unpublished; fi gure 6). Transmission of the virus within 
families rather than the peer-group at school could lead to 
increased incidence of severe cases, as the inoculum 
concentration is thought to be higher.85 Data from clinical 
and epidemiological studies are needed to guide public 
health decisions. 
Vaccine development
No vaccines against EV71 exist, but by analogy with 
poliomyelitis, vaccination probably off ers the best option 
for disease control. One limitation in EV71 vaccine 
development is the lack of a good mouse model of human 
disease. Adult mice are resistant to infection. Although 
suckling mice are susceptible, by the time immunity 
develops after inoculation, the animals have matured and 
become resistant to infection. One way around this issue 
is to vaccinate female adult mice, allow them to become 
pregnant, and then measure titres of protective maternal 
antibodies transferred to off spring, as judged by 
protection against lethal infection.117 
In human beings the target population should be 
young children, especially those younger than 3 years, 
because they are the most susceptible to severe disease. 
One important issue is whether vaccines derived against 
one EV71 genetic subgroup will provide cross-protection 
against all others; available data are contradictory.76–78 
Several comprehensive reviews on the development of 
EV71 vaccine candidates have been published.118,119 Various 
types of vaccines are being investigated, including 
inactivated whole-virus, live attenuated, subviral particle, 
and DNA vaccines. All types are in early stages of 
development, with the most advanced undergoing 
preclinical trials in mice and non-human primates. 
Candidate inactivated vaccines include those derived in 
Taiwan from the B4 viruses EV71-075 and EV71-0117, 
which are highly immunogenic, and from EV71-1207, 
which is a C2 virus and is less immunogenic. In one 
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study all these vaccines were more immunogenic in mice 
than recombinant VP1 protein or DNA vectored 
vaccines.120 Virus-like particles for EV71, which resemble 
the virus in appearance and capsid and protein structure, 
have been produced and purifi ed as potential vaccines.121 
After immunisation of BALB/c mice, the particles 
induced potent and long-lasting humoral immune 
responses, refl ected by high total IgG and neutralisation 
titres. Splenocytes collected from the immunised mice 
exhibited substantial cell proliferation and stimulated 
production of interferon γ and interleukins 2 and 4, 
indicating the induction of T-helper-1 and T-helper-2 
immune responses. Immunisation of female mice 
conferred protection (survival up to 89%) to neonatal 
mice against virus challenge with a dose 1000 times that 
normally required to kill 50% of animals.121 
A potential DNA vaccine has been developed by 
inserting the VP1 gene into the pVAX1 vector, and 
transforming the constructs into Escherichia coli cells, 
followed by expression in a mammalian cell line.122 
Immunisation of mice with the DNA vaccine constructs 
resulted in the production of antibodies to VP1 IgG and 
neutralising antibody against EV71. Oral immunisation 
of female mice with an attenuated Salmonella enterica 
serovar Typhimurium expressing the VP1 gene, also 
proved protective in newborn off spring.123 Transgenic 
tomatoes expressing the VP1 protein have been 
developed. Incorporation of this protein in an oral 
vaccine led to the development of VP1-specifi c antibodies 
and evidence of cell-mediated immunity in BALB/c mice, 
and provided protection to off spring in neonatal 
challenge models.124
Linear neutralising epitopes from the VP1 capsid protein 
were identifi ed in mice by raised concentrations of antisera 
against overlapping peptides from this protein, two of 
which elicited neutralising antibody responses.125 One of 
these peptides, SP70, was especially potent, and comparison 
with sequences from other strains showed it was conserved 
among the diff erent genotypic subgroups of EV71, which 
suggests it is a promising vaccine candidate.
A live attenuated strain of EV71, EV71(S1-3), was derived 
from the genotype A prototype strain BrCr by genetic 
manipulation,126 on the basis of temperature-sensitive 
determinants of poliovirus type 1 vaccine strain, some of 
which are located in the 5´and 3´untranslated regions 
and the 3Dpol gene. Intravenous inoculation of 
cynomolgus monkeys led to the production of antibodies 
with cross-reactivity against a broad spectrum of EV71 
genotypes that survived challenge with intravenous 
virulent EV71 (BrCr-TR strain), which is lethal to non-
immunised monkeys. However, the vaccine strain itself 
caused mild neurological symptoms (tremor) and entered 
the spinal cord, which indicated that further work on 
attenuation is needed.126 
Among the various vaccine candidates, inactivated 
whole virus vaccines are in some ways the most ready to 
develop further, because the principles of vaccines based 
on inactive whole virus are well established. However, 
experience with vaccination against Japanese encephalitis, 
another major neurological infection in Asia, has shown 
that issues over cost and availability can limit the 
widespread uptake of vaccines in poor Asian countries. If 
a vaccine is to be used across the whole of Asia, it needs 
to be cheap, easily produced, and readily available.127 
Conclusions
The increased size and frequency of EV71 outbreaks in the 
Asia-Pacifi c region over the past 12 years has been an 
important public health issue. Molecular epidemiological 
studies suggest that some viral genotypic subgroups seem 
Figure 6: Comparison of data from sentinel surveillance centres on eff ects of public health interventions on hand, foot, and mouth disease in Sarawak, 
Malaysia, in 2003 and 2006
The public health response was limited in 2003, but more-rigorous social distancing measures were encouraged in 2006.
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to have massive potential for explosive epidemics, whereas 
others have more-indolent, low-level circulation. However, 
the biological determinants of these diff erences are poorly 
understood. The reasons for epidemiological diff erences 
between EV71 in the Asia-Pacifi c region and that in Europe 
and the USA are also unclear, as are the virological and 
host determinants of the wide-ranging clinical phenotypes 
in infected individuals. Although some animal models of 
neurological disease caused by EV71 are reasonable, a 
good model of cardiorespiratory dysfunction is urgently 
required to help understand pathogenesis better. 
The public health measures currently used during 
EV71 epidemics are empirical and generic, have high 
socioeconomic impact and are not clearly eff ective. 
Further research is needed on virus transmission. The 
identifi cation of several EV71 receptors might help in 
drug discovery. Several vaccine candidates are under 
development, but the logistical issues of how to reach 
their target paediatric populations remain important. 
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